How does the microbiome affect liver disease?
Herbert Tilg, Christoph Grander, Alexander R. Moschen – 30 November 2016
Epidemiology of nonalcoholic steatohepatitis and hepatocellular carcinoma
Christian Dominik Fingas, Jan Best, Jan‐Peter Sowa, Ali Canbay – 30 November 2016
Reply
Marco Laudo, Matteo Ravaioli, Gaetano Manna, Giorgia Comai, Matteo Cescon, Massimo Gaudio, Valentina Bertuzzo, Chiara Zanfi, Alessandro Cucchetti, Antonio Daniele Pinna – 24 November 2016
Anti‐inflammatory signaling during ex vivo liver perfusion improves the preservation of pig liver grafts before transplantation
Davide Ghinolfi, Laura Caponi, Lorella Marselli, Daniele Pezzati, Maria Franzini, Paolo De Simone, Vanna Fierabracci, Piero Marchett, Aldo Paolicchi, Franco Filipponi – 24 November 2016
Disability in patients with end‐stage liver disease: Results from the functional assessment in liver transplantation study
Mariya L. Samoylova, Kenneth E. Covinsky, Marta Haftek, Selena Kuo, John P. Roberts, Jennifer C. Lai – 24 November 2016 – Cirrhosis leads to sarcopenia and functional decline that can severely impact one's ability to function at home and in society. Self‐reported disability scales to quantify disability—Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL)—are validated to predict mortality in older adults.
Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges
Giovanni Musso, Maurizio Cassader, Elena Paschetta, Roberto Gambino – 23 November 2016
A novel glucagon‐like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice
M. Pilar Valdecantos, Virginia Pardo, Laura Ruiz, Luis Castro‐Sánchez, Borja Lanzón, Elisa Fernández‐Millán, Carmelo García‐Monzón, Ana I. Arroba, Águeda González‐Rodríguez, Fernando Escrivá, Carmen Álvarez, Francisco J. Rupérez, Coral Barbas, Anish Konkar, Jacqui Naylor, David Hornigold, Ana Dos Santos, Maria Bednarek, Joseph Grimsby, Cristina M. Rondinone, Ángela M.
Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost‐effectiveness analysis
Matthew J. Klebanoff, Kathleen E. Corey, Jagpreet Chhatwal, Lee M. Kaplan, Raymond T. Chung, Chin Hur – 23 November 2016 – Nonalcoholic steatohepatitis (NASH) affects 2%‐3% of the US population and is expected to become the leading indication for liver transplantation in the next decade. Bariatric surgery may be an effective but expensive treatment for NASH. Using a state‐transition model, our analysis assessed the effectiveness and cost‐effectiveness of surgery to manage NASH.
Low‐Dose Lipopolysaccharide Causes Biliary Injury by Blood Biliary Barrier Impairment in a Rat Hepatic Ischemia/Reperfusion Model
Janske Reiling, Kim R. Bridle, Marion Gijbels, Frank G. Schaap, Lesley Jaskowski, Nishreen Santrampurwala, Laurence J. Britton, Catherine M. Campbell, Steven W. M. Olde Damink, Darrell H. G. Crawford, Cornelius H. C. Dejong, Jonathan Fawcett – 23 November 2016 – This study explored whether bacterial endotoxins, in the form of lipopolysaccharides (LPS), could have an injurious effect on the biliary tract in conjunction with ischemia.
Vascular complications in living donor liver transplantation at a high‐volume center: Evolving protocols and trends observed over 10 years
Shiraz Ahmad Rather, Mohammed A. Nayeem, Shaleen Agarwal, Neerav Goyal, Subash Gupta – 23 November 2016 – Vascular complications continue to have a devastating effect on liver transplantation recipients, even though their nature, incidence, and outcome might have actually changed with increasing experience and proficiency in high‐volume centers. The aim of this study was to analyze the trends observed in vascular complications with changing protocols in adult and pediatric living donor liver transplantation over 10 years in 2 time frames in terms of nature, incidence, and outcome.